@article{fec3cbb919ec4728b0b10beb92a30330,
title = "Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987",
abstract = "The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor activity and might improve survival.",
keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Cisplatin, Deoxycytidine, Disease-Free Survival, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Neutropenia, Paclitaxel, Survival Analysis, Thrombocytopenia, Treatment Outcome, Urologic Neoplasms, Urothelium",
author = "Joaquim Bellmunt and {von der Maase}, Hans and Mead, {Graham M} and Iwona Skoneczna and {De Santis}, Maria and Gedske Daugaard and Andreas Boehle and Christine Chevreau and Luis Paz-Ares and Laufman, {Leslie R} and Eric Winquist and Derek Raghavan and Sandrine Marreaud and Sandra Collette and Richard Sylvester and {de Wit}, Ronald",
year = "2012",
doi = "10.1200/JCO.2011.38.6979",
language = "English",
volume = "30",
pages = "1107--13",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",
}